Compare ABSI & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABSI | CYRX |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United States | United States |
| Employees | N/A | 1100 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.9M | 419.3M |
| IPO Year | 2021 | 2008 |
| Metric | ABSI | CYRX |
|---|---|---|
| Price | $3.23 | $10.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $7.47 | ★ $12.94 |
| AVG Volume (30 Days) | ★ 3.9M | 399.7K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.64 | ★ 156.22 |
| EPS | N/A | ★ 1.40 |
| Revenue | $4,534,000.00 | ★ $176,177,000.00 |
| Revenue This Year | $631.04 | $11.06 |
| Revenue Next Year | $75.73 | $8.45 |
| P/E Ratio | ★ N/A | $7.19 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.24 | $5.21 |
| 52 Week High | $5.23 | $11.45 |
| Indicator | ABSI | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.70 | 72.51 |
| Support Level | $2.38 | $9.18 |
| Resistance Level | $3.27 | $10.23 |
| Average True Range (ATR) | 0.19 | 0.41 |
| MACD | 0.02 | 0.18 |
| Stochastic Oscillator | 80.77 | 94.55 |
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.